Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Hyseq, Inc. (NasdaqNM:HYSQ)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 30Price hit new 52-week low ($7.30)
Location
670 Almanor Avenue
Sunnyvale, CA 94086
Phone: (408) 524-8100
Fax: (408) 524-8106
Email: ir@sbh.com
Employees (last reported count): 257
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 29%
·Over the last 6 months:
 · one insider buy; 2.24M shares (92.9% of insider shares)
 · one insider sell; 11.0K shares
  (0.5% of insider shares)
·Institutional: 14% (19% of float)
(77 institutions)
·Net Inst. Selling: 908.0K shares (+69.42%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Hyseq, Inc. is engaged in the research and development of novel biopharmaceutical products from its collection of proprietary genes discovered using its high-throughput screening-by-hybridization platform. The Company's activities have focused primarily on full-length gene sequencing, patenting, bioinformatics and early stage research activities to prioritize its therapeutic protein candidates. As of March 1, 2001, the Company had filed patent applications on more than 5,600 full-length gene sequences. It is advancing two molecules, IL-1Hy1, with potential applications for inflammatory diseases, and CD39L4, with potential applications for heart disease, into development in order to generate data required to file an Investigational New Drug application with the Food and Drug Administration. The Company's database includes genes that encode chemokines, growth factors, stem cell factors, interferons, integrins, hormones, receptors and other potential protein therapeutics or drug targets.
More from Market Guide: Expanded Business Description

Financial Summary
HYSQ applies the proprietary DNA array technology of its integrated HyX genomics platform to develop gene-based therapeutic product candidates and diagnostic products and tests. For the six months ended 6/30/01, revenues totaled $11.6 million, up from $5.4 million. Net loss increased 32% to $15.1 million. Revenues reflect higher revenues earned from a collaboration with BASF Plant Sciences GmbH. Net loss reflects increased R&D expenses due to additional personnel.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Pay

George Rathmann, 72
Chairman
--  
Ted Love, M.D.
Pres, CEO
--  
Robert Weist, 60
Vice Chairman
--  
Peter Garcia
CFO, Sr. VP
--  
Radoje Drmanac, Ph.D., 42
CSO and Director
$268K
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:HYSQAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Aug-2001
$7.30 
Recent Price$7.40 
52-Week High
on 5-Sep-2000
$43.625
Beta1.67 
Daily Volume (3-month avg)113.5K
Daily Volume (10-day avg)112.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-82.8%
52-Week Change
relative to S&P500
-77.0%
Share-Related Items
Market Capitalization$118.7M
Shares Outstanding16.0M
Float11.4M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.86 
Earnings (ttm)-$1.82 
Earnings (mrq)-$0.55 
Sales (ttm)$1.55 
Cash (mrq)$0.40 
Valuation Ratios
Price/Book (mrq)8.63 
Price/EarningsN/A 
Price/Sales (ttm)4.77 
Income Statements
Sales (ttm)$21.9M
EBITDA (ttm)-$22.3M
Income available to common (ttm)-$25.9M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-83.63%
Return on Equity (ttm)-168.84%
Financial Strength
Current Ratio (mrq)0.91 
Debt/Equity (mrq)0.43 
Total Cash (mrq)$6.34M
Short Interest
As of 8-Aug-2001
Shares Short407.0K
Percent of Float3.6%
Shares Short
(Prior Month)
341.0K
Short Ratio6.46 
Daily Volume63.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.